As far as M2-polarized (CD163+) TAMs are concerned, results from several retrospective series support their negative prognostic role in unselected early BC patients as well as in TNBC and HER2+ subgroups [101,109,110,111]. The gene discussed is ERBB2; the disease is breast cancer.